

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/750,878	01/05/2004	Hans-Michael Eggenweiler	MERCK-2412-D01	3232
23599 75	590 07/05/2006		EXAMINER	
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.			HUI, SAN MING R	
2200 CLAREN SUITE 1400	DON BLVD.		ART UNIT	PAPER NUMBER
ARLINGTON,	VA 22201		1617	

DATE MAILED: 07/05/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No.	Applicant(s)		
10/750,878	EGGENWEILER ET AL	EGGENWEILER ET AL.	
Examiner	Art Unit		
San-ming Hui	1617		

Advisory Action Before the Filing of an Appeal Brief --The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 10 April 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: The period for reply expires <u>3</u> months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). **NOTICE OF APPEAL** 2. The Notice of Appeal was filed on 15 June 2006. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). **AMENDMENTS** 3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below): (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: _____. (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a) i will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: None. Claim(s) objected to: None. Claim(s) rejected: 5-8. Claim(s) withdrawn from consideration: 9. AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER 11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet. 12. Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s). 13. ☐ Other: .

> an-ming Hui Primary Examiner Art Unit: 1617

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's arguments with regard to restriction practice that requires the search to be extended have been considered, but are not found persuasive. Examiner notes that for the claim language to be "Markush-type", "The members of the Markush group (A, B, and C in the example above) ordinarily must belong to a recognized physical or chemical class or to an art-recognized class." See MPEP 803.02. In the instant case, the members of the group do not belong to a physical, chemical or art-recognized class. In the contrary, the disorders recited (the members of the Markush group) are generally recognized in the art as unrelated disorders. For example, Sepsis is a severe infection in the blood caused by bacteria. It is totally unrelated, with respect to treatment, etiologies, and pathophysiology, to for example, osteoporosis. In the same way, atherosclerosis is not related to asthma or cancer. In other words, these diseases, as recognized in the arts are unrelated, not belonging to the same class. Therefore, there is no need to extend the search to other disorders recited in the claims.

Applicant's arguments with regard to the outstanding rejection under 35 USC 112, first paragraph have been considered, but are not found persuasive. Applicant particularly argues that Contar reference approach that the paragraph have been considered, but are not found persuasive.

persuasive. Applicant particularly argues that Carter reference suggests that some drugs do not interact with tumors located in various areas listed, while others do. Therefore, it could not be probative evidence required by Marzocchi. Examiner notes that it is precisely the point that there is no one class of compounds that would work for all tumors, since not all compounds can interact with all tumor types, let alone treating it. The instant claims are so broad that they encompass all and every kind of tumors. In view of the teachings of Carter, one of skilled in the art would have to perform undue experimentation to ascertain the appropriate embodiments to practice the full scope of the claims.

No unanswered arguments are seen to be present herein. .